Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma

Urology

Volumn 61, Issue 2, 2003, Pages 314-319

  Han, Ken Ryu ^a   Pantuck, Allan J ^a   Bui, Matthew H T ^a   Shvarts, Oleg ^a   Freitas, Danielo G ^a   Zisman, Amnon ^a   Leibovich, Bradley C ^a   Dorey, Frederick J ^a   Gitlitz, Barbara J ^a   Figlin, Robert A ^a   Belldegrun, Arie S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 DERIVATIVE;

ADULT; ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037319254     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02163-5     Document Type: Article

References (24)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47.
2. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med. 335:1996;865-875.
3. Figlin R.A. Renal cell carcinoma management of advanced disease . J Urol. 161:1999;381-387.
4. Mani S., Todd M.B., Katz K., et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 154:1995;35-40.
5. Ljungberg B., Landberg G., Alamdari F.I. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol. 34:2000;246-251.
6. Kuczyk M.A., Bokemeyer C., Kohn G., et al. Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Br J Urol. 80:1997;18-24.
7. Pantuck A.J., Zisman A., Chao D., et al. Regional lymphadenopathy during cytoreductive nephrectomy predicts IL-2 failure in patients with metastatic renal cell carcinoma. Proc ASCO. 20:2001;172A.
8. Tongaonkar H.B., Dandekar N.P., Dalal A.V., et al. Renal cell carcinoma extending to the renal vein and inferior vena cava results of surgical treatment and prognostic factors . J Surg Oncol. 59:1995;94-100.
9. Nesbitt J.C., Soltero E.R., Dinney C.P., et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg. 63:1997;1592-1600.
10. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:1982;655-663.
11. Storkel S., Eble J.N., Adlakha K., et al. Classification of renal cell carcinoma Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) . Cancer. 80:1997;987-989.
12. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
14. Cox D., Oakes D. Analysis of Survival Data. 1990;Chapman and Hall, New York.
15. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 17:1999;2530-2540.
16. Citterio G., Bertuzzi A., Tresoldi M., et al. Prognostic factors for survival in metastatic renal cell carcinoma retrospective analysis from 109 consecutive patients . Eur Urol. 31:1997;286-291.
17. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48:1988;7310-7313.
18. Palmer P.A., Vinke J., Philip T., et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 3:1992;475-480.
19. Canobbio L., Rubagotti A., Miglietta L., et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha. J Cancer Res Clin Oncol. 121:1995;753-756.
20. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma a randomised trial . Lancet. 358:2001;966-970.
21. Pantuck A.J., Belldegrun A.S., Figlin R.A. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 345:2001;1711-1712.
22. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 345:2001;1655-1659.
23. Kankuri M., Pelliniemi T.T., Pyrhonen S., et al. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma a phase II study . Cancer. 92:2001;761-767.
24. Tsuda S., Koga S., Nishikido M., et al. Evaluation of bone metastases from renal cell carcinoma. Hinyokika Kiyo. 47:2001;155-158.